Genflow Biosciences
GENF · Main Market · Health Care · mcap £11m · 1.8p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 09 Oct 26 | Corporate Update
Japanese patent granted for SIRT6 variants; additional animal health companies sign confidentiality agreements. |
−2.2% | |
| 05 Oct 26 | Results | Presentation of Interim Results
SLAB canine study interim results show SIRT6c gene therapy reduced epigenetic age and was well tolerated. |
−13.3% |
| 29 Sep 26 | Exercise of Warrants and Issue of Equity
Genflow (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a biotechnology company focused on the development of gene therapies for age-related diseases announces that it has received notices of exercise of warrant |
+0.0% | |
| 29 Sep 26 | Results | Half-year Results
Completed lead canine trial validating SIRT6 platform; raised £1.1m in H1 2026; expanded into glaucoma program. |
+0.0% |
| 08 Sep 26 | Primary Endpoint in SLAB Clinical Trial Met
SLAB clinical trial met primary endpoint in SIRT6 gene therapy trial in aged dogs with biological age reduction. |
−2.4% | |
| 07 Sep 26 | Appointment of Investor Relations Adviser
Genflow appoints ON365 Partners as investor relations adviser, replacing Harbor Access. |
+13.1% | |
| 03 Aug 26 | Patent Update
SIRT6 patent application for NAFLD published; Track One prioritized examination granted for foundational US patent. |
+16.4% | |
| 13 Jul 26 | Mid-Year Operational and Corporate Summary
SLAB dog trial shows sustained safety and efficacy at three-month follow-up; non-dilutive Acuitas LNP collaboration secured. |
−1.3% | |
| 29 Jun 26 | Routine | Result of AGM | |
| 22 Jun 26 | Participation at BIO International Convention 2026
Independent Non-Executive Chairman attending BIO International Convention 2026 panel on RNA therapeutics. |
+3.7% | |
| 17 Jun 26 | Company to present at Animal Longevity Summit 2026
Genflow invited to present SLAB trial data at Animal Longevity Summit in October 2026. |
−1.2% | |
| 04 Jun 26 | Routine | Notice of AGM | |
| 08 May 26 | Exercise of Warrants and Issue of Equity
Genflow (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a biotechnology company focused on the development of gene therapies for age-related diseases announces that it has received notices of exercise of warrant |
−7.7% | |
| 30 Apr 26 | Results | Final Results
FY25 results show progress in dog aging trial, MASH repositioning, and shift to mRNA delivery technology. |
−1.1% |
| 28 Apr 26 | Expansion of Confidentiality Agreements
Expanded confidentiality agreements with Tier-1 animal health companies for canine SIRT6 gene therapy programme review. |
+12.0% | |
| 20 Apr 26 | Strategic Technology Collaboration
Genflow enters fully funded collaboration with Acuitas to integrate LNP delivery technology with its SIRT6 mRNA platform. |
+16.9% | |
| 13 Apr 26 | International Patent Publication
Patent Cooperation Treaty application published for SIRT6 variants for muscular disease treatment. |
+10.3% | |
| 08 Apr 26 | Update on the Dog Study
SLAB trial shows sustained safety and efficacy three months post-dosing in aged dogs receiving SIRT6 gene therapy. |
−9.1% | |
| 31 Mar 26 | Routine | Total Voting Rights | |
| 05 Mar 26 | Director dealing | Issue of Equity & PDMR Notifications | |
| 02 Mar 26 | Result of General Meeting
Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company focusing on longevity, is pleased to announce that all resolutions proposed at the General Meet |
−5.0% | |
| 02 Mar 26 | Receipt of First Tranche of Grant
Received first tranche of €336,467 from €4 million Wallonia Region grant for GF-1002 development. |
−5.0% | |
| 12 Feb 26 | Results | Preliminary Interim Results From Dog Study
SLAB trial of SIRT6 gene therapy in aged dogs shows survival benefit and safety with improvements in muscle mass and frailty. |
+0.0% |
| 11 Feb 26 | Notice of GM
Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces that the Board is c |
−9.5% | |
| 30 Jan 26 | Holding | Holding(s) in Company | |
| 28 Jan 26 | Administrative Approval of Grant & 2026 Priorities
€4 million non-dilutive funding from Wallonia Region administratively approved for GF-1002 development. |
−2.6% | |
| 19 Jan 26 | Board change | Directorate Change
Gad Berdugo appointed Independent Non-Executive Chairman; Tamara Joseph continues as Director. |
+5.4% |
| 08 Jan 26 | Review of 2025
Genflow completed dog aging trial dosing with no adverse events; expects efficacy readout Q1 2026 and plans pipeline rationalization. |
+0.0% | |
| 16 Dec 25 | Completion of Dosing Phase of Canine Gene Therapy
Completed dosing phase of canine SIRT6 gene therapy trial with no adverse events reported. |
+1.4% | |
| 11 Dec 25 | Genflow to Attend Healthcare Conference
Genflow to attend the J.P. Morgan Healthcare Conference in January 2026. |
−11.5% | |
| 31 Oct 25 | Routine | Total Voting Rights | |
| 24 Oct 25 | Holding | Holding(s) in Company | |
| 22 Oct 25 | Second European Patent Application
Second European patent application for SIRT6 variant for NASH published in European Patent Bulletin. |
−0.9% | |
| 20 Oct 25 | Recognition of Patentability of Claims
European Patent Office published SIRT6 variant patent application, entering final pre-grant phase. |
−4.4% | |
| 10 Oct 25 | Update on Animal Health Program
SIRT6 gene therapy administered second time in dog aging study with no adverse effects reported. |
+1.9% | |
| 09 Oct 25 | Director dealing | Update, Equity Issue and PDMR Notification
Terminated prior fundraise; raised £440k via share issue to CEO and existing shareholders at 1.1p per share plus warrants. |
+90.9% |
Company filings. Not investment advice.